|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
R, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Cervantes A, Nordlinger B
and Arnold D; ESMO Guidelines Working Group, : Metastatic
colorectal cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 25 (Suppl 3):iii1–iii9. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Montagnani F, Chiriatti A, Turrisi G,
Francini G and Fiorentini G: A systematic review of FOLFOXIRI
chemotherapy for the first-line treatment of metastatic colorectal
cancer: Improved efficacy at the cost of increased toxicity.
Colorectal Dis. 13:846–852. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cersosimo RJ: Management of advanced
colorectal cancer, Part 1. Am J Health Syst Pharm. 70:395–406.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cersosimo RJ: Management of advanced
colorectal cancer, Part 2. Am J Health Syst Pharm. 70:491–506.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mohelnikova-Duchonova B, Melichar B and
Soucek P: FOLFOX/FOLFIRI pharmacogenetics: The call for a
personalized approach in colorectal cancer therapy. World J
Gastroenterol. 20:10316–10330. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu HW and Cho WC: The emerging role of
miRNAs in combined cancer therapy. Expert Opin Biol Ther.
15:923–925. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao Y and Srivastava D: A developmental
view of microRNA function. Trends Biochem Sci. 32:189–197. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weng W, Okugawa Y, Toden S, Toiyama Y,
Kusunoki M and Goel A: FOXM1 and FOXQ1 Are promising prognostic
biomarkers and novel targets of Tumor-Suppressive miR-342 in human
colorectal cancer. Clin Cancer Res. 22:4947–4957. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weng W, Feng J, Qin H, Ma Y and Goel A: An
update on miRNAs as biological and clinical determinants in
colorectal cancer: A bench-to-bedside approach. Future Oncol.
11:1791–1808. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Irwandi RA and Vacharaksa A: The role of
microRNA in periodontal tissue: A review of the literature. Arch
Oral Biol. 72:66–74. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang G, Pan J, Ye Z, Fang B, Cheng W and
Cao Z: Overexpression of miR-216b sensitizes NSCLC cells to
cisplatin-induced apoptosis by targeting c-Jun. Oncotarget.
8:104206–104215. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Du X, Liu B, Luan X, Cui Q and Li L:
miR-30 decreases multidrug resistance in human gastric cancer cells
by modulating cell autophagy. Exp Ther Med. 15:599–605.
2018.PubMed/NCBI
|
|
14
|
Zhou X, Natino D, Zhai X, Gao Z and He X:
MicroRNA22 inhibits the proliferation and migration, and increases
the cisplatin sensitivity, of osteosarcoma cells. Mol Med Rep.
17:7209–7217. 2018.PubMed/NCBI
|
|
15
|
Salendo J, Spitzner M, Kramer F, Zhang X,
Jo P, Wolff HA, Kitz J, Kaulfuß S, Beißbarth T, Dobbelstein M, et
al: Identification of a microRNA expression signature for
chemoradiosensitivity of colorectal cancer cells, involving
miRNAs-320a,-224,-132 and let7g. Radiothe Oncol. 208:451–457. 2013.
View Article : Google Scholar
|
|
16
|
Ye Q, Su L, Chen D, Zheng W and Liu Y:
Astragaloside IV induced miR-134 expression reduces EMT and
Increases chemotherapeutic sensitivity by suppressing CREB1
signaling in colorectal cancer cell line SW-480. Cell Physiol
Biochem. 43:1617–1626. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tokarz P and Blasiak J: The role of
microRNA in metastatic colorectal cancer and its significance in
cancer prognosis and treatment. Acta Biochim Pol. 59:467–474. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li XJ, Ren ZJ and Tang JH: MicroRNA-34a: A
potential therapeutic target in human cancer. Cell Death Dis.
5:e13272014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Xie T, Mao X, Xue L, Chu X and Chen
L: MicroRNA-149 increases the sensitivity of colorectal cancer
cells to 5-Fluorouracil by targeting forkhead box transcription
factor FOXM1. Cell Physiol Biochem. 39:617–629. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dabkeviciene D, Jonusiene V, Zitkute V,
Zalyte E, Grigaitis P, Kirveliene V and Sasnauskiene A: The role of
interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of
human colorectal carcinoma cells HCT116. Med Oncol. 32:2582015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource:targets and expression. Nucleic
Acids Res. 36((Database Issue)): D149–D153. 2008.PubMed/NCBI
|
|
23
|
Betel D, Koppal A, Agius P, Sander C and
Leslie C: Comprehensive modeling of microRNA targets predicts
functional non-conserved and non-canonical sites. Genome Biol.
11:R902010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Boyer J, McLean EG, Aroori S, Wilson P,
McCulla A, Carey PD, Longley DB and Johnston PG: Characterization
of p53 wild-type and null isogenic colorectal cancer cell lines
resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin
Cancer Res. 10:2158–2167. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yao Z, Bhandari A, Wang Y, Pan Y, Yang F,
Chen R, Xia E and Wang O: Dihydroartemisinin potentiates antitumor
activity of 5-fluorouracil against a resistant colorectal cancer
cell line. Biochem Biophys Res Commun. 501:636–642. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lai Z, Yan Z, Chen W, Peng J, Feng J, Li
Q, Jin Y and Lin J: Hedyotis diffusa Willd suppresses metastasis in
5-fluorouracil-resistant colorectal cancer cells by regulating the
TGF-β signaling pathway. Mol Med Rep. 16:7752–7758. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu B, Liu Y, Zhao L, Pan Y, Shan Y, Li Y
and Jia L: Upregulation of microRNA-135b and microRNA-182 promotes
chemoresistance of colorectal cancer by targeting ST6GALNAC2 via
PI3K/AKT pathway. Mol Carcinog. 56:2669–2680. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao C, Zhao Q, Zhang C, Wang G, Yao Y,
Huang X, Zhan F, Zhu Y, Shi J, Chen J, et al: miR-15b-5p
resensitizes colon cancer cells to 5-fluorouracil by promoting
apoptosis via the NF-KB/XIAP axis. Sci Rep. 7:41942017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xie T, Geng J, Wang Y, Wang L, Huang M,
Chen J, Zhang K, Xue L, Liu X, Mao X, et al: FOXM1 evokes
5-fluorouracil resistance in colorectal cancer depending on ABCC10.
Oncotarget. 8:8574–8589. 2017.PubMed/NCBI
|
|
31
|
Hou Y, Zhu Q, Li Z, Peng Y, Yu X, Yuan B,
Liu Y, Liu Y, Yin L, Peng Y, et al: The FOXM1-ABCC5 axis
contributes to paclitaxel resistance in nasopharyngeal carcinoma
cells. Cell Death Dis. 8:e26592017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hollis M, Nair K, Vyas A, Chaturvedi LS,
Gambhir S and Vyas D: MicroRNAs potential utility in colon cancer:
Early detection, prognosis, and chemosensitivity. World J
Gastroenterol. 21:8284–8292. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tian L, Zhao Z, Xie L and Zhu J:
MiR-361-5p inhibits the mobility of gastric cancer cells through
suppressing epithelial-mesenchymal transition via the Wnt/β-catenin
pathway. Gene. 675:102–109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Han J, Yu J, Dai Y, Li J, Guo M, Song J
and Zhou X: Overexpression of miR-361-5p in triple-negative breast
cancer (TNBC) inhibits migration and invasion by targeting RQCD1
and inhibiting the EGFR/PI3K/Akt pathway. Bosn J Basic Med Sci.
19:52–59. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li R, Dong B, Wang Z, Jiang T and Chen G:
MicroRNA-361-5p inhibits papillary thyroid carcinoma progression by
targeting ROCK1. Biomed Pharmacother. 102:988–995. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li L, Wu D, Yu Q, Li L and Wu P:
Prognostic value of FOXM1 in solid tumors: A systematic review and
meta-analysis. Oncotarget. 8:32298–32308. 2017.PubMed/NCBI
|
|
38
|
Cao S, Lin L, Xia X and Wu H: MicroRNA-761
promotes the sensitivity of colorectal cancer cells to
5-Fluorouracil through targeting FOXM1. Oncotarget. 9:321–331.
2017.PubMed/NCBI
|
|
39
|
Anreddy N, Patel A, Sodani K, Kathawala
RJ, Chen EP, Wurpel JN and Chen ZS: PD173074, a selective FGFR
inhibitor, reverses MRP7 (ABCC10)-mediated MDR. Acta Pharm Sin B.
4:202–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sun YL, Chen JJ, Kumar P, Chen K, Sodani
K, Patel A, Chen YL, Chen SD, Jiang WQ and Chen ZS: Reversal of
MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PLoS
One. 8:e555762013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao
H, Gong C, Chen J, Su F, Zhang Y and Song E: Reduced miR-128 in
breast tumor-initiating cells induces chemotherapeutic resistance
via Bmi-1 and ABCC5. Clin Cancer Res. 17:7105–7115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hagmann W, Faissner R, Schnölzer M, Löhr M
and Jesnowski R: Membrane drug transporters and chemoresistance in
human pancreatic carcinoma. Cancers (Basel). 3:106–125. 2010.
View Article : Google Scholar : PubMed/NCBI
|
